CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) — Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the closing of its previously announced registered direct offering of common stock and of pre-funded warrants, with gross proceeds of the offering totaling approximately $110 million. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
The offering includes new investors BVF Partners, Deerfield Management and other leading healthcare specialist investors as well as other new and previous investors, including founding investor Flagship Pioneering. Jefferies, TD Cowen and Evercore ISI acted as joint book-running managers for the offering.
“We are pleased with the continued support from existing long-term investors and the quality of the new investors as we further advance our pipeline and our programs with the goal of delivering meaningful therapeutics to patients,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “This financing allows us to advance our programs through multiple data readouts and clinical value inflection points as we continue to develop medicines for patients and create value for shareholders. It supports our already strong balance sheet and extends our runway into 2027.”
The Company issued 12,743,039 shares of its common stock at a public offering price of $5.51 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 7,220,794 shares of its common stock at a public offering price of $5.5099 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn.
